IMCR
Immunocore Holdings plc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Immunocore Holdings plc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
—
No other changes.
No other changes.
No thesis.
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
No peers for Immunocore Holdings plc yet.
No peers for Immunocore Holdings plc yet.
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Immunocore Holdings plc
30.46
−0.81 · −2.60%
post 30.46 0.00%
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| Wellington | $181.7M | 10.84% | +21.58% |
| RTW | $154.6M | 9.23% | 0.00% |
| FMR | $136.8M | 8.16% | −10.81% |
| Primecap | $115.5M | 6.89% | −1.49% |
| Bellevue | $88.5M | 5.28% | −0.31% |
| Manager | Value | % base | |
|---|---|---|---|
| Wellington | $181.7M | 10.84% | +21.58% |
| RTW | $154.6M | 9.23% | 0.00% |
| FMR | $136.8M | 8.16% | −10.81% |
| Primecap | $115.5M | 6.89% | −1.49% |
| Bellevue | $88.5M | 5.28% | −0.31% |
Expected move
Inputsstraddle ±12.1%
spot 30.49exp Nov 20ATM strike 30ATM straddle 4.32IV 74%
—
—